Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman

Rhea-AI Summary

Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced that Panetta Partners Limited, linked to Executive Chairman Gabriele Cerrone, purchased 29,318 common shares at prices between $0.78 and $0.81, increasing Cerrone's stake from 37.70% to 37.72%. The company focuses on developing innovative drug delivery technologies for immunotherapies, with two lead candidates showing favorable safety and efficacy in clinical studies. Tiziana aims to enhance immunotherapy efficacy through alternative delivery methods such as nasal and oral routes.

Positive

• Gabriele Cerrone increased ownership stake in Tiziana from 37.70% to 37.72%.
• Tiziana's lead candidates have demonstrated favorable safety profiles in clinical studies.

Negative

• None.

NEW YORK, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 29,318 common shares priced between $0.78 and $0.81 per share.

The acquisition takes Mr Cerrone's interests from 37.70% to 37.72%.

About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s two lead candidates, intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have both demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

For further inquiries:

Tiziana Life Sciences Ltd
Hana Malik, Business Development, and Investor Relations Manager  
+44 (0) 207 495 2379
email: info@tizianalifesciences.com  

Investors:
Irina Koffler
LifeSci Advisors, LLC
646.970.4681
ikoffler@lifesciadvisors.com

FAQ

What recent share acquisition occurred for Tiziana Life Sciences (TLSA)?

Panetta Partners Limited, associated with Gabriele Cerrone, purchased 29,318 common shares of Tiziana at prices between $0.78 and $0.81, increasing Cerrone's interest to 37.72%.

What are the lead candidates of Tiziana Life Sciences?

Tiziana's lead candidates include intranasal foralumab and milciclib, both showing favorable clinical responses.

How does Tiziana Life Sciences deliver its therapies?

Tiziana employs innovative nasal, oral, and inhalation approaches for drug delivery, aimed at improving efficacy and safety compared to traditional IV methods.